{"schema_version":"secwatch.filing_event.v1","accession":"0001214659-24-017549","form_type":"8-K","ticker":"ALZN","cik":"0001677077","company_name":"Alzamend Neuro, Inc.","filed_at":"2024-10-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.198042+00:00","generated_at":"2026-05-30T14:37:15.794100+00:00","sec_items":["7.01","3.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Alzamend Neuro regains Nasdaq compliance; avoids delisting","bullets":["Received written notice from Nasdaq Hearings Panel on Oct 14, 2024 that it has regained compliance with minimum stockholders' equity rule ($2.5M required).","Had been notified of delisting in March 2024, appealed to Panel, granted extension until Sept 23, 2024.","Entered $25M Series A Convertible Preferred purchase agreement; $8M already funded, additional $2M due in 30 days, $1M monthly through Jan 2026.","CEO Stephan Jackman states strategic plan executed; company intends to initiate five phase II AL001 trials in 2025 with Massachusetts General Hospital."],"urls":{"canonical":"https://secwatch.observer/filing/0001214659-24-017549","json":"https://secwatch.observer/filing/0001214659-24-017549.json","markdown":"https://secwatch.observer/filing/0001214659-24-017549.md","text":"https://secwatch.observer/filing/0001214659-24-017549.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1677077/000121465924017549/0001214659-24-017549-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1677077/000121465924017549/o10142408k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T14:37:15.794100+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}